Go Ahead and Advertise--If You Dare
This article was originally published in RPM Report
Executive Summary
Congress agrees with the pharmaceutical industry that the right to advertise new drugs is protected by the First Amendment. But pharma companies have a long way to go to prove to their critics that it is the right thing to do.
You may also be interested in...
DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns
FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.
DTC Public Health Slant: A Winning Formula With FDA Commissioner Hamburg
FDA Commissioner Margaret Hamburg is not taking the easy way out when she discusses DTC, even in front of Congressional critics of the practice. She does not treat DTC as primarily a regulatory problem for the agency; instead she likes to focus on the public health potential of DTC.
DTC Public Health Slant: A Winning Formula With FDA Commissioner Hamburg
FDA Commissioner Margaret Hamburg is not taking the easy way out when she discusses DTC, even in front of Congressional critics of the practice. She does not treat DTC as primarily a regulatory problem for the agency; instead she likes to focus on the public health potential of DTC.